Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease

Medical Hypotheses

Volumn 73, Issue 5, 2009, Pages 659-661

  Knobloch, Karsten ^a   Redeker, Joern ^a   Vogt, Peter M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN II ANTAGONIST; ANTIFIBROTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGENASE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INTERFERON; SMAD PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; DRUG MECHANISM; DRUG POTENTIATION; DUPUYTREN CONTRACTURE; FIBROGENESIS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DUPUYTREN CONTRACTURE; FIBROSIS; HUMANS; MODELS, THEORETICAL; RECURRENCE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70349737543     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.08.011     Document Type: Article

References (18)

1. Rehman S., Salway F., Stanley J.K., Ollier W.E., Day P., and Bayat A. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg [Am] 33 (2008) 359-372
2. Larson D., and Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review. BMC Musculoskelet Disord 9 (2008) 104
3. Rayan G.M. Nonoperative treatment of Dupuytren's disease. J Hand Surg [Am] 33 7 (2008) 1208-1210
4. Kraljevic Pavelic S., Sedic M., Hock K., Vucinic S., Jurisic D., Gehrig P., et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 217 4 (2009) 524-533
5. Moyer K.E., Banducci D.R., Graham III W.P., and Ehrlich H.P. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 110 1 (2002) 187-193
6. Seyhan H., Kopp J., Schultze-Mosgau S., and Horch R.E. Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. Plast Reconstr Surg 117 4 (2006) 1248-1252
7. Alioto R.J., Rosier R.N., Burton R.I., and Puzas J.E. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg [Am] 19 3 (1994) 442-452
8. Badalamente M.A., Sampson S.P., Hurst L.C., Dowd A., and Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg [Am] 21 2 (1996) 210-215
9. Kuhn M.A., Wang X., Payne W.G., Ko F., and Robson M.C. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren's affected palmar fascia. J Surg Res 103 2 (2002) 146-152
10. Bayat A., Watson J.S., Stanley J.K., Ferguson M.W., and Ollier W.E. Genetic susceptibility to dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg 111 7 (2003) 2133-2139
11. Seifert O., and Mrowitz U. Keloid scarring: bench and bedside. Arch Dermatol Res 301 4 (2009) 259-272
12. Colwell A.S., Phan T.T., Kong W., Longaker M.T., and Lorenz P.H. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor beta stimulation. Plast Reconstr Surg 116 5 (2005) 1387-1390
13. Bulbuller N., Ilhan Y.S., Kirkil C., Cetiner M., Gogebakan O., and Ilhan N. Can angiotensin converting enzyme inhibitors prevent postoperative adhesions?. J Surg Res 125 1 (2005) 94-97
14. Mazahri M.K., Schultz G.S., Blalock T.D., Caffee H.H., and Chin G.A. Role of connective tissue growth factor in breast implant elastomer capsular formation. Ann Plast Surg 50 3 (2003) 263-268
15. Zimman O.A., Toblii J., Stella I., Ferder M., Ferder L., and Inserra F. The effects of angiotensin-converting-enzyme inhibitors on the fibrous envelope around mammary implants. Plast Reconstr Surg 120 7 (2007) 2025-2033
16. Yu L., Border W.A., Anderson I., McCourt M., Huang Y., and Noble N.A. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effects. Kidney Int 66 5 (2004) 1774-1784
17. Degreef I., Vererfve P.B., and De Smet L. Effect of severity of Dupuytren contracture on disability. Scand J Plast Reconstr Surg Hand Surg 43 1 (2009) 41-42
18. Smith R.P., Dias J.J., Ullah A., and Bhowal B. Visual and computer software-aided estimates of Dupuytren's contractures: correlation with goniometric measurements. Ann R Coll Surg Engl 41 4 (2009) 296-300